Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024 report and make more profitable business decisions.
Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands and feet.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Argenx SECellenkos Inc
Cresence AS
CSPC NBP Pharmaceutical Co Ltd
Dianthus Therapeutics Inc
GeNeuro SA
Immunovant Inc
Immupharma Plc
Johnson & Johnson
Kine Sciences
Octapharma AG
Sanofi
Serpin Pharma LLC
Takeda Pharmaceutical Co Ltd
Zai Lab Ltd
Zenyaku Kogyo Co Ltd
Table of Contents
Table
Figures
Frequently asked questions